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Objectives: Hemophilia is a hereditary, lifelong bleeding disorder. Patients are defi-
cient in either coagulation factor VIII (hemophilia A) or IX (hemophilia B). This study 
is aimed to assess the economic impact of these conditions in Mexico. MethOds: 
In this cost-of-illness study, both direct medical costs (diagnosis, follow-up, prophy-
laxis and on-demand coagulation factor replacement therapy, inpatient and outpa-
tient care of hemorrhages and complications) and indirect costs related with loss of 
productivity in either adult patients or in parents of affected children along one year 
were assessed. Local demographic and epidemiological data (last update: 2011), as 
well as annual bleeding rates in both prophylaxis and on-demand approaches were 
extracted from published sources. Resource use patterns were derived mainly from 
Mexican Clinical Practice Guidelines co-authors (n= 8) through a survey. Unitary 
costs of medical resources were gathered mainly from Instituto Mexicano del Seguro 
Social (IMSS) sources. It is assumed that productivity losses of adult patients/par-
ents of hemophiliac children are proportional to the number of days in hospital; 
average per hour wage and worked hours per week were extracted from National 
Statistics Office database. All costs are expressed in 2013 USD. Results: A total of 
3906 (87%) type A and 597 (13%) type B patients comprised the 2011 documented 
prevalence of hemophilia in Mexico. Most (57%) of all patients received medical care 
at IMSS. Direct medical costs (79.3 USD millions) and indirect costs (370,398 USD) 
accounted for 99.5% and 0.5% of total costs (79.7 USD millions), respectively. Among 
direct medical costs, acquisition of coagulation factors represented the most impor-
tant category (55.1 USD millions, 69.23%), followed by non-pharmacological care of 
hemorrhages (20 USD million, 25.12%). Average cost per patient was very similar: 
18,152 and 14,662 USD for type A and B, respectively. cOnclusiOns: Despite its low 
prevalence, hemophilia imposes a considerably high economic burden in Mexico´s 
health care system.
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Objectives: : Estimate the cost of treatment of IH previous to introduction of pro-
pranolol in the treatment of haemangioma; Infantile haemangioma is a common 
lesion affecting around 10% of children. At least 30% of haemangiomas require 
treatment. MethOds: Observational multicentric retrospective study at five expert 
centres treating children with haemangioma. The first 10 patient records, from each 
centre, of patients having been diagnosed, between the age of one and five months 
before 31/12/2007, with a haemangioma measuring > 1.5 cm in diameter, having 
already received corticosteroid treatment, were identified and selected. Results: 
53 children were included. Haemangioma was mixed (cutaneous and subcutane-
ous) in 69.0% of children, and was located on the head and neck in 88.7% of cases. 
Complications arose in 75.5% of children. 83.0% of the children underwent addi-
tional tests in view of diagnosis and treatment of haemangioma. Tests most often 
included an MRI-scan (39.6%), an ophthalmological examination (30.2%) or heart 
ultrasound (32.1%). A dermatologist followed the patients in 71.7% of cases. 69.8% 
of the children were admitted to hospital at least once for their haemangioma and 
17.0% had laser treatment. The average cost of treatment (according to the health 
insurance fund) of children with haemangioma was high, reaching € 6,407.00 on 
average. The highest expenditure item was hospitalisation at an average cost of 
€ 5,337.00 (equivalent to 83% of the total average cost). cOnclusiOns: IH has a 
significant medical and financial impact, requiring relatively heavy medical treat-
ment (numerous medical consultations with various specialists, frequent additional 
tests, long-term medication and surgery and laser treatment), the impact being even 
more significant the more serious the haemangioma. Introduction of propranolol in 
the treatment of IH should reduce treatment costs appreciably, notably by reducing 
the length of the hospital stays.
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Objectives: IV PCA equipment and opioid cost analyses on specific procedures are 
lacking. This study estimates the IV PCA hospital cost for the first 48 postoperative 
hours for 3 inpatient surgeries. MethOds: Descriptive analyses using the Premier 
database (2010~2012) of > 500 US hospitals were conducted on cost of IV PCA after 
total knee or hip arthroplasty (TKA or THA) or open abdominal surgeries. Weighted 
average cost of each component was aggregated for total costs. Direct acquisition and 
indirect cost (labor, pharmacy, etc.) were included. Results: Of 11,805,513 patients, 
272,443 (2.3%), 139,275 (1.2%) and 195,062 (1.7%) patients had TKA, THA and abdominal 
surgeries, respectively, with 20% of TKA and abdominal and 23% THA patients having 
specific IV PCA charges. Morphine (57%) and hydromorphone (44%) were the most 
frequently used PCA drugs, with the mean cost per 30 cc syringe of $16 (30 mg) and $21 
(6 mg), respectively. Number of syringes for morphine and hydromorphone were 1.9 
and 3.2 (TKA), 2.0 and 4.2 (THA), 2.5 and 3.9 (abdominal). Average costs of PCA pump, 
IV tubing set and drug ranged from $46 to $48, $20 to $22 and $33 to $46, respectively. 
Pump, tubing and saline required to maintain patency of IV PCA catheter over 48 hours 
ranged from $9 to $13, $8 to $9, and $20 to $22, respectively. Supplemental opioids 
during IV PCA use ranged from a low of $56 for THA to $87 for abdominal surgeries. 
Aggregated mean IV PCA/opioid total costs per patient were $196 (THA), $203 (TKA) 
and $243 (abdominal surgeries). cOnclusiOns: Although IV PCA is a 40-year old 
technology, the cost of equipment and opioid drugs in these postoperative patients is 
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Objectives: The aim of this study was to estimate the social cost of the three 
main bariatric surgery techniques used for the treatment of morbid obesity: gastric 
banding (GB), gastric by-pass (GBP), and sleeve gastrectomy (SG). MethOds: The 
study was designed as longitudinal multicenter survey. Adult patients in charge 
to 6 Hospital Centers in Italy have been enrolled at the time of the intervention 
and followed up to 1 year. Direct medical costs have been estimated using tariffs 
for laboratory tests, diagnostic exams, visits, and prices for drugs. Inpatient cost 
data have been collected at the Center level, as well as the costs of intervention. 
Non medical costs included costs for travel and accommodation, domestic help 
and informal care. The loss of productivity of patients have been estimated using 
the human capital approach. Costs are reported as mean (± standard deviation) in 
Euro 2013. Results: 301 patients have been enrolled and 1 year after the interven-
tion a BMI reduction of 19%, 35% and 29% have been observed for GB, GBP and SG 
respectively. The social cost of the intervention amounted to € 6,853 (± € 1,328) for 
GB, € 9,934 (± € 3,370) for GBP and € 8,840 (± € 1,766) for SG. The social annual cost 
in the year after the intervention has been estimated as € 2,421 (± € 2,036) for GB 
(of these 31% were direct non medical costs and 36% were indirect costs), € 3,019 (± 
€ 2,428) for GBP (of these 43% were direct non medical costs and 22% were indirect 
costs) and € 2,518 (± € 2.083) for SG (of these 43% were direct non medical costs and 
24% were indirect costs). cOnclusiOns: As compared to GB and SG, GBP was most 
effective with higher costs of intervention and follow up.
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Objectives: Umbilical cord blood graft (CBG) is an option for hematopoietic stem 
cell transplantation (HSCT) where bone marrow or peripheral stem-cell trans-
plant (BM/PB) is not possible. Compared to traditional CBG, expanded CBG (ECBG) 
improves survival and clinical outcomes including median times to platelet and 
absolute neutrophil count engraftment, chronic and acute graft-versus-host dis-
ease (GvHD) and relapse rate. We assessed the costs and cost-effectiveness from 
the societal perspective of implementing ECBG in Canada. MethOds: Economic 
and epidemiologic models were developed using the results of a literature review 
and hospital data analysis, and included direct and indirect costs (e.g. productivity 
costs). We compared (1) BM/PB with unrelated donors (UD), (2) double umbilical 
cord blood graft (DUCB), (3) expanded umbilical cord blood graft (EUCB) with one or 
two cords (optimistic and conservative scenarios) in patients without an option for 
matched-related donors. Results: Total treatment (direct) costs comprised bone 
marrow and cord procurement (18-36%), donor search (16-19%), hospitalization 
(14-18%), and pharmacy (10-14%). DUCB costs were the highest of the different 
options, totalling $210,000, followed by EUCB (conservative; $206,000, optimistic; 
$174,000) and UD ($172,000). Adding indirect costs totaled DUCB $400,000, UD 
$376,000 and EUCB conservative $376,000; optimistic $343,000 (Canadian dol-
lars). Rate of GvHD had the largest impact on indirect costs through prevent-
ing return to work (lower productivity). The ICER using the direct costs only for 
EUCB vs UD was $500 (optimistic) to $7300 (conservative) per QALY. When the 
societal costs are accounted for, EUCB is an economically dominant treatment 
option. cOnclusiOns: When comparing direct costs EUCB is less expensive for 
the health care system than DUCB, but more expensive than UD. When comparing 
overall societal costs including direct and indirect costs EUCB was least expensive, 
likely due to lower rate of GvHD.
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Objectives: Examine health care utilization/costs among fibromyalgia (FM) or 
painful diabetic peripheral neuropathy (pDPN) patients with and without prior 
authorization (PA) within the benefit structure of a large geographically diverse 
US commercial health insurance plan. MethOds: Patients diagnosed (via claims-
based algorithm) with FM or pDPN were included. Index date was the date of first 
FM- or pDPN-related pharmacy claim observed within intake period (07/01/2007-
12/31/2011). Separately for FM/pDPN, health care utilization and cost outcomes 
were assessed. Using four-to-one (PA to no PA) propensity score matching (PSM), 
patients enrolled in pharmacy plans with PA benefit design (PA group) were matched 
to patients enrolled in pharmacy plans without PA (no PA group). We used a differ-
ence in differences (DiD) analysis and two independent groups ttest to compare 
differences in mean cost between cohorts from pre-index to post-index periods. A 
p-value < 0.05 indicated a statistical difference between the two groups. Results: 
29,746 patients met inclusion criteria in the FM cohort. 29,283 (98.4%) patients were 
identified in the PA group and 463 (1.6%) in the no PA group. For all-cause costs in the 
FM cohort, the mean DiD between no PA and PA cohorts was $-197 (p= 0.6673); for 
disease-related costs, the mean DiD was $-72 (p= 0.4186). A total of 14,233 patients 
met inclusion criteria for the pDPN cohort. Of that total, 13,973 (98.2%) were identi-
fied in the PA group and 260 (1.8%) were in the no PA group. For all-cause costs in the 
pDPN cohort, the mean DiD between no PA and PA cohorts was $1,155 (p= 0.6248); 
for disease-related costs, the mean DiD was $-2,809 (p= 0.4312). cOnclusiOns: For 
patients with FM and separately for patients with pDPN, we compared pre-index 
and post-index costs and differences in costs between PA and no PA. The results 
of our investigation indicate that implementation of a PA may not reduce cost.
